CD44 and metastatic malignant neoplasm in the lymph nodes: In OSCC specifically, Tripathi et al. [37] conducted a meta-analysis restricted to immunohistochemical CSC markers—mainly CD44, CD24, CD133, and ALDH—and reported that CD133 expression was associated with poorer survival, whereas ALDH expression correlated with lymph node metastasis and advanced clinical stage.